Starting later this year, Ouro intends to start a phase 1 clinical trial of its own, eyeing the development of the drug for ...

A recent study reveals the pivotal role of tristetraprolin (TTP), an RNA-binding protein, in regulating inflammatory responses in basophils, immune cells central to allergic reactions. The research ...

Challenge trials help researchers study immune responses. Skeptics still doubt the approach is worth the risks ...

Following the negative Phase I trial outcome for its autoimmune disease treatment, the company is cutting 73% of jobs.

Reaching more mUM patients globally with KIMMTRAK (tebentafusp) in 2025 through additional launches and increased community penetration Enrolling three Phase 3 trials across multiple melanoma ...

IGM Biosciences Inc. said Thursday it is cutting 73% of its workforce after deciding to halt further development of a program relating to its autoimmunity-drug pipeline, sending its stock down 69% in ...

Andrew Heys, 29, suffered a severe reaction to a Covid booster vaccine in 2021 and developed a life-changing auto-immune ...

Ouro is planning to leverage T cell engagers to deplete B cells and “reset” the immune system to treat immune-mediated ...

Prenatal exposure to glucocorticoids is associated with some mental disorders in offspring, such as mood, anxiety, and stress ...

Largest ever protein study set to revolutionise cancer and dementia tests - Tens of millions of pounds in investment is being provided by the group of firms which includes AstraZenecaa and Pfizer ...

Women diagnosed with advanced breast cancer appeared more likely than those with earlier-stage breast cancer to have ...

Armed with $115 million and a clinical-stage asset, another player is emerging in the increasingly crowded T cell engager ...